PI3K inhibitors as new cancer therapeutics: Implications for clinical trial design

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 203-210

  Massacesi, Cristian ^a   di Tomaso, Emmanuelle ^b   Urban, Patrick ^c   Germa, Caroline ^c   Quadt, Cornelia ^d   Trandafir, Lucia ^a   Aimone, Paola ^c   Fretault, Nathalie ^a   Dharan, Bharani ^c   Tavorath, Ranjana ^c   Hirawat, Samit ^c  

^a Novartis Oncology   (France)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS PHARMA K K   (Japan)

Author keywords

Biomarkers; Clinical trial design; Patient selection; PI3K inhibitors; PI3K AKT mTOR pathway

Indexed keywords

ALPELISIB; BEVACIZUMAB; BUPARLISIB; CARBOPLATIN; CETUXIMAB; DOCETAXEL; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FULVESTRANT; IDELALISIB; LAPATINIB; LETROZOLE; LOMUSTINE; NAVELBINE; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; TEMOZOLOMIDE; TRASTUZUMAB;

ADVANCED CANCER; B CELL LYMPHOMA; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STUDY DESIGN; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 84954357527     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S89967     Document Type: Review

References (38)

1. Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13(5):1021–1031.
2. Fritsch C, Huang A, Chatenay-Rivauday C, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014;13(5):1117–1129.
3. Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11(2):317–328.
4. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143–153.
5. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008;11(1–2):32–50.
6. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2002;5(6): 234–248.
7. Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013;71(4):829–842.
8. Massacesi C, di Tomaso E, Fretault N, Hirawat S. Challenges in the clinical development of PI3K inhibitors. Ann N Y Acad Sci. 2013;1280: 19–23.
9. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011;13(6):224.
10. André F, O’Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580–591.
11. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529.
12. Hortobagyi G, Piccart-Gebhart M, Rugo H, et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol. 2013;31 Suppl:LBA509.
13. Mayer IA, Abramson VG, Isakoff SJ, et al. Stand up to cancer phase IB study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2014;32(12):1202–1209.
14. Brana I, Siu LL. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med. 2012;10:161.
15. Juric D, Gonzalez-Angulo A, Burris H, et al. Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: results from a phase I study. Cancer Res. 2013;73:P2-16-14.
16. Juric D, Argiles G, Burris HA, et al. Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC). Cancer Res. 2012;72:P6-10-07.
17. Hurvitz SA, André F, Jiang Z, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015;16(7):816–829.
18. Slamon DJ, Hurvitz SA, Chen D, et al. Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: combined exploratory analysis from BOLERO-1 and BOLERO-3. J Clin Oncol. 2015;33 Suppl:512.
19. Baselga J, Cortés J, Im SA, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Poster presented at: 35th Annual San Antonio Breast Cancer Symposium; December 4–8, 2012; San Antonio, TX.
20. Saura C, Bendell J, Jerusalem G, et al. Phase IB study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res. 2014;20(7):1935–1945.
21. Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013;3(7):761–769.
22. Fokas E, Im JH, Hill S, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 2012;72(1):239–248.
23. Huang A, Fritsch C, Wilson C, et al. Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel. Cancer Res. 2012;72:3749.
24. Sheng Q, Wang HQ, Das R. Targeting HER3 and PI3K in head and neck squamous cancer cells. Cancer Res. 2013;73:4261.
25. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2012;23(6):1518–1525.
26. Razak ARA, Ahn M, Yen C, et al. Phase lB/ll study of the PI3Kα inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN). J Clin Oncol. 2014;32(5 Suppl):6044.
27. Dy GK, Vansteenkiste J, Thomas M, et al. Epidemiology of PI3K pathway alterations in patients with metastatic non-small cell lung cancer (NSCLC): findings from the international BASALT-1 study. Poster presented at: 15th World Conference on Lung Cancer; October 27–31, 2013; Sydney, Australia.
28. Vansteenkiste J, Canon JL, De Braud F, et al. Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated nonsmall cell lung cancer (NSCLC): results from the phase II BASALT-1 study. J Thorac Oncol. 2015;10(9):1319–1327.
29. Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol. 2004;94(3):785–795.
30. Lee S, Choi EJ, Jin C, Kim DH. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005;97(1):26–34.
31. Tan D, Lim K, Tai W, et al. A phase IB safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC. J Clin Oncol. 2013;31 Suppl:8107.
32. Chantry D, Vojtek A, Kashishian A, et al. P110δ, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with P85 and is expressed predominantly in leukocytes. J Biol Chem. 1997;272(31): 19236–19241.
33. Zang C, Eucker J, Liu H, et al. Inhibition of pan-class I phosphatidylinositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55(2):425–434.
34. Younes A, Salles G, Bociek RG, et al. An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma. Poster presented at: 56th ASH Annual Meeting and Exposition; December 6–9, 2014; San Francisco, CA.
35. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–1068.
36. Maira M, Schnell C, Lollini P, et al. Preclinical and preliminary clinical activity of NVP-BKM120, an oral pan-class I PI3K inhibitor, in the brain. Ann Oncol. 2012;23 Suppl 9:ix537.
37. Wen PY, Lee EQ, Reardon DA, Ligon KL, Yung WK. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012;14(7):819–829.
38. Wen P, Yung WK, Mellinhoff IK, et al. Phase II trial of the phosphatidylinositol (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma. J Clin Oncol. 2014;32(5 Suppl):2019.